National

EU court says public employees may be barred from wearing head scarf

Nov 29, 2023

Brussels [Belgium], November 29: The top European Union court ruled on Tuesday that public authorities in member states can prohibit employees from wearing signs of religious belief, such as an Islamic head scarf, in the latest decision on an issue that has divided Europe for years.
The case came to the Court of Justice of the European Union (CJEU) after an employee of the eastern Belgian municipality of Ans was told she could not wear an Islamic head scarf at work.
The municipality subsequently changed its terms of employment to require its employees to observe strict neutrality by not wearing overt signs of religious or ideological belief.
The woman concerned launched a legal challenge, saying her right to freedom of religion had been infringed.
The hijab, the traditional head scarf worn around the head and shoulders, has been a divisive issue across Europe for years.
The municipality subsequently changed its terms of employment to require its employees to observe strict neutrality by not wearing overt signs of religious or ideological belief.
The woman concerned launched a legal challenge, saying her right to freedom of religion had been infringed.
The hijab, the traditional head scarf worn around the head and shoulders, has been a divisive issue across Europe for years.
It was for a national court to verify that these requirements are complied with.
Source: Fijian Broadcasting Corporation

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025